Member Login
  1. Stocks
    2. /
  2. HUTCHMED (LSE: HCM)
    3. /

LSE:HCM (HUTCHMED)

About HCM

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

HUTCHMED (LSE: HCM) Latest News

Investing Articles

This AIM-listed 20-bagger is the best stock I never bought

| Harvey Jones

Harvey Jones names his single biggest regret as an investor, but claims he's over it now.

Read more »

Investing Articles

Don’t worry about the State Pension! These 2 pharma stocks could make you VERY wealthy

| Royston Wild

The pharmaceuticals space is full of great shares that could make you a fortune. Just like these two AIM-quoted beauties.

Read more »

Hulk monster
Investing Articles

2 monster stocks in the making I’d buy for 2018

| Bilaal Mohamed

Bilaal Mohamed looks at two AIM-listed companies with huge long-term growth potential.

Read more »

Investing Articles

This remarkable nine-bagger has further to go

| Harvey Jones

Don't let this China-focused biopharmaceutical company slip away, says Harvey Jones.

Read more »

Investing Articles

This forgotten growth stock deserves more attention

| Jack Tang

Can this growth stock's "unusual" strategy help it to deliver attractive long-term returns?

Read more »

Investing Articles

Does cancer breakthrough make this stock a better buy than AstraZenenca plc?

| Bilaal Mohamed

Should investors ditch AstraZeneca plc (LON:AZN) in favour of this promising AIM-listed biotech firm?

Read more »

Investing Articles

What are the safest places to store your money post-Brexit?

| Royston Wild

Royston Wild reveals a cluster of Footsie stars that could thrive despite current financial fears.

Read more »

Investing Articles

Pharma fight! Should you buy GlaxoSmithKline plc, Smith & Nephew plc or Hutchison China MediTech Limited?

| Royston Wild

Royston Wild considers whether GlaxoSmithKline plc (LON: GSK), Smith & Nephew plc (LON: SN) or Hutchison China MediTech Limited (LON:…

Read more »

Investing Articles

Should You Follow Directors Buying Shares At Standard Chartered PLC, Hutchison China MediTech Limited And Britvic Plc?

| G A Chester

Should you pile into Standard Chartered PLC (LON:STAN), Hutchison China MediTech Limited (LON:HCM) and Britvic Plc (LON:BVIC) as directors buy?

Read more »

Investing Articles

Could AIM Stars ASOS Plc, Telit Communications Plc And Hutchison China MediTech Limited Fund Your Retirement?

| Ian Pierce

Has the City overlooked a slew of small cap winners with ASOS Plc (LON: ASC), Telit Communications Plc (LON: TCM)…

Read more »

Investing Articles

3 Emerging Market Stars Set To Explode: Vodafone Group plc, PZ Cussons plc & Hutchison China Meditech Limited

| Royston Wild

Royston Wild explains why Vodafone Group plc (LON: VOD), PZ Cussons plc (LON PZC) and Hutchison China Meditech Limited (LON:…

Read more »

Investing Articles

Are Unilever plc, Ted Baker plc, SABMiller PLC And Hutchison China MediTech Limited The Hottest Emerging Market Stocks Out There?

| Royston Wild

Royston Wild explains the merits of investing in Unilever plc (LON: ULVR), Ted Baker plc (LON: TED), SABMiller PLC (LON:…

Read more »